Filing Flows

Filing Flows › Health Care › Haemonetics (HAE)

Haemonetics (HAE) earnings and revenue breakdown

Latest: Q2 FY27 · 10-Q filed Nov 5, 2026 · Haemonetics (HAE) Q2 FY27 earnings results →

Q2 FY27 Revenue up 9% year over year to $358M · 13¢ of every $1 of revenue kept as net profit · operating margin 21.0%

Haemonetics made $358M in Q2 FY27 (+9% Y/Y): Apheresis $205M, MedSurg $153M. Operating margin 21.0%, net earnings $46.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.

Revenue$358M
Year over year+9%
Operating margin21.0%
Net earnings$46.3M
Operating cash flow$128M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $357.8M in Q2 FY27, up 9% year over year and up 5% from the previous quarter. Apheresis was the largest line at 57% of revenue. Apheresis added $23.0M year over year (up 13%), 76% of the total change.

Gross margin was 61.7%, up 2.3 points from Q2 FY26. Operating profit was $75.1M, a 21.0% margin (up 3.1 points year over year). Of the extra revenue versus Q2 FY26, 55% reached operating profit, above the 18% margin then. Operating expenses grew 7% against revenue growth of 9%. The fastest-growing cost line was SG&A (+16%). Net earnings were $46.3M, up 20% year over year. The effective tax rate was 26.3%.

Operating cash flow was $128.1M (up 15% year over year), 277% of net earnings. Non-cash charges added back $27.8M of depreciation and amortization and $10.2M of share-based compensation. Working capital and other items added $43.8M. Capital expenditures of $14.8M left free cash flow of $113.3M.

Quarterly history

Haemonetics revenue by quarterHaemonetics revenue by quarter$331MQ4 FY25$321MQ1 FY26$327MQ2 FY26$339MQ3 FY26$346MQ4 FY26$339MQ1 FY27$358MQ2 FY27
Haemonetics net earnings by quarterHaemonetics net earnings by quarter$58.0MQ4 FY25$34.0MQ1 FY26$38.7MQ2 FY26$44.7MQ3 FY26−$20.1MQ4 FY26$33.0MQ1 FY27$46.3MQ2 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q2 FY2710-QNov 5, 2026$358M+9%21.0%$46.3M$128M
Q1 FY2710-QAug 6, 2026$339M+6%16.9%$33.0M$52.3M
Q4 FY2610-KMay 20, 2026$346M+5%-6.6%−$20.1M$70.9M
Q3 FY2610-QFeb 5, 2026$339M-3%19.9%$44.7M$93.6M
Q2 FY2610-QNov 6, 2025$327M-5%17.9%$38.7M$111M
Q1 FY2610-QAug 7, 2025$321M-4%16.8%$34.0M$17.4M
Q4 FY2510-KMay 21, 2025$331M-4%21.6%$58.0M$117M

Charts

Haemonetics: revenue growth, year over year and quarter over quarterHaemonetics: revenue growth, year over year and quarter over quarterY/YQ/Q-4%Q4 FY25-4%-3%Q1 FY26-5%+2%Q2 FY26-3%+4%Q3 FY26+5%+2%Q4 FY26+6%-2%Q1 FY27+9%+5%Q2 FY27
Latest (Q2 FY27): Y/Y +9%, Q/Q +5%.
Haemonetics: where the cash came from (+) and went (−), TTM to Q2 FY27Haemonetics: where the cash came from (+) and went (−), TTM to Q2 FY27Operating cash flow$345MOther investing−$118MBuybacks−$100MNet borrowing (+) / repaid (−)−$100MCapital spending−$46.7MCash drawn (+) / kept (−)$35.7MOther financing−$14.5MTaxes on employees’ shares−$4.1MAsset & business sales$1.8MExchange rates$563K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Haemonetics: profit against cash, quarter by quarterHaemonetics: profit against cash, quarter by quarterNet incomeOperating cash flow$37.5M$43.8MQ3 FY25$58.0M$117MQ4 FY25$34.0M$17.4MQ1 FY26$38.7M$111MQ2 FY26$44.7M$93.6MQ3 FY26−$20.1M$70.9MQ4 FY26$33.0M$52.3MQ1 FY27$46.3M$128MQ2 FY27
Latest (Q2 FY27): Net income $46.3M, Operating cash flow $128M.
Haemonetics: diluted shares by fiscal yearHaemonetics: diluted shares by fiscal year51MFY2151MFY2251MFY2351MFY2451MFY2547MFY26
-7.7% since FY21: buybacks shrank the count.
Haemonetics: long-term debt falling due (FY26)Haemonetics: long-term debt falling due (FY26)$7.9M2027$12.6M2028$18.8M2029$1.2B2030$77K2031$401KLater
Cash $245M, short-term investments —, long-term debt $1.2B at 2026-03-28.
Haemonetics in its industry: growth against margin (111 companies, SIC 3841)Haemonetics in its industry: growth against margin (111 companies, SIC 3841)revenue growth, year over year →↑ operating marginmedian +10%median -9%MDLNMMMSYKBSXBDXBAXSOLVRMDDXCMWSTMMEDPODDGMEDTFXICUIMMSIIARTPENTNDMEMBCIRTCATECGKOSOFIXINSPNVCRUFPTATRCBVSAORTPRCTTCMDARAYANGOKIDSSKINLMATHTFLMDXGCERSSIBNTMCISTIMINFUBBNXKMTSOSURANIKDCTHRCELSGHTIRMDXTNTLUNGNPCEPDEXTELACARLLNSRSIMOBIAPYXSSIICVRXCLPTKRMDTLSIPROFSNWVCTSOIDXGUTMDRVPSNOAPREMNEPHDRIOVVOSBTCYNXGLMDAIMDNCPMINONE.SRTSSINTIVFNMTCNSPRAURXXAIRLUCDTNONINBSRNXTVTAKUSAQICUVYCOHRGNCNSYPLSEPETVFEMYOSRHCODXOBIORDGLPAVMGUTSHAE (+9%, 21%)
Surgical & Medical Instruments & Apparatus; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Haemonetics

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. When used in this report, the terms “we,” “us,” “our,” “Haemonetics” and the “Company” mean Haemonetics Corporation.

In its own words, from its 10-K, filed May 20, 2026.

Haemonetics against its Surgical & Medical Instruments & Apparatus peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +9% against the peers' median +5%. Operating margin: 21.0% against the peers' median 15.9%.

CompanyQuarterRevenueY/YOp. margin
HAE HaemoneticsQ2 FY27$358M+9%21.0%
MDLN MedlineQ3 2026$7.9B+10%6.4%
MMM 3MQ3 2026$6.6B+1%23.7%
SYK StrykerQ3 2026$6.5B+8%15.9%
BSX Boston ScientificQ3 2026$5.1B+1%16.1%
BDX Becton DickinsonQ3 FY26$5.0B+5%13.3%
BAX Baxter InternationalQ3 2026$3.0B+5%7.6%
SOLV SolventumQ3 2026$1.9B-7%3.5%
RMD ResMedQ1 FY27$1.4B+6%32.0%

Source: Haemonetics 10-Q on SEC EDGAR · CIK 313143 · Surgical & Medical Instruments & Apparatus

Guidance and outlook

Haemonetics: what its forward-looking statements are about (10-Q filed 2026-11-05)Haemonetics: what its forward-looking statements are about (10-Q filed 2026-11-05)Deals2People1The economy1
4 statements; tone +0.75 (−1 all cautious, +1 all confident); 2 hedged.
Haemonetics: outlook statements against the filing beforeHaemonetics: outlook statements against the filing beforeConfident3

13F: who owns HAE and who is buying

Largest holders of HAE (13F)Largest holders of HAE (13F)BlackRock$443MVanguard Group$382MNeuberger Berman Group LLC$313MVanguard Portfolio Management LLC$191MAQR Capital Management LLC$165MAriel Investments, LLC$155MVanguard Capital Management LLC$154MState Street$136MDimensional Fund Advisors LP$119MCitadel Advisors LLC$113M
Funds' net buying of HAE by quarter (13F)Funds' net buying of HAE by quarter (13F)−$112M2024-09$44.1M2024-12−$251M2025-03$28.4M2025-06−$189M2025-09$67.3M2025-12−$238M2026-03$169M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on HAE

History

Every quarter: Q2 FY27 results · Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results

Compare HAE with

中文版：Haemonetics（HAE）财报

Español · Français